Towards genomics-assisted breeding of medical marijuana

迈向基因组学辅助医用大麻育种

• 批准号: 491543-2015
• 负责人: Myles, Sean
• 金额: $ 1.82万
• 依托单位: Dalhousie University
• 依托单位国家: 加拿大
• 项目类别: Engage Grants Program
• 财政年份: 2015
• 资助国家: 加拿大
• 起止时间: 2015-01-01 至 2016-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=586951
• 关键词: Towards; genomics; assisted; breeding; medical

BedroCan is a leading licensed producer of medical marijuana in Canada. Its R&D department has identified a set of compounds in marijuana that influence consumer preference and medicinal effect. Their aim is to breed novel marijuana strains with specific profiles of these compounds. But this task is challenging: performing detailed chemical tests of thousands of offspring in their breeding programme is prohibitively time consuming and expensive. They have a clear breeding target but cannot achieve it on their own. The proposed project will foster a new partnership between BedroCan and the Myles lab that will develop the first genomics-assisted breeding toolkit for marijuana. By the end of the project timeline, we will identify a novel set of genetic markers that BedroCan's breeders can use to identify improved strains with the desired chemical profiles at the seedling stage, without the need to grow them to maturity and perform expensive chemical tests. Not only will this accelerate BedroCan's breeding programme, but the new knowledge from this project will generate valuable intellectual property for BedroCan. Furthermore, the aim is to then further develop the resulting IP into a commercial genetic test to be licensed to others, providing a potential novel source of revenue for the company. The discoveries from this project will not only lend legitimacy to a rapidly growing, multi-billion dollar industry in need of scientific input, but it will also accelerate the improvement of marijuana strains that attain higher consumer acceptance and better medical outcomes for Canadians.

贝德罗坎是加拿大领先的有执照的医用大麻生产商。其研发部门已经确定了一种 大麻中影响消费者偏好和药效的一组化合物。它们的目标是繁衍后代 具有这些化合物特定特征的新型大麻菌株。但这项任务具有挑战性：执行 在繁育计划中对数以千计的后代进行详细的化学测试非常耗时 而且很贵。它们有明确的繁殖目标，但单靠自己是无法实现的。 拟议的项目将促进贝德罗坎和迈尔斯实验室之间的新合作伙伴关系，该实验室将开发 首个用于大麻的基因组学辅助育种工具包。到项目时间表结束时，我们将确定一个 一组新的遗传标记，贝德罗坎的饲养员可以用来识别具有所需基因的改良菌株 苗期的化学成分，而不需要生长到成熟和执行昂贵的 化学测试。这不仅将加速贝德罗坎的育种计划，而且还将获得来自 该项目将为贝德罗坎创造宝贵的知识产权。此外，我们的目标是进一步 将生成的IP开发为商业基因测试，以授权给其他公司，提供潜在的创新 公司的收入来源。该项目的发现不仅将为快速的 不断增长的、价值数十亿美元的行业需要科学投入，但它也将加速改善 为加拿大人获得更高的消费者接受度和更好的医疗结果的大麻品种。